Hematopoietic Stem Cell Transplantation in Solid Tumors

Yıl 2014, Cilt: 23 Sayı: 1, 90 - 96, 30.10.2014

Serhan Küpeli

https://doi.org/10.17827/aktd.15325

Öz

Children suffering from lymphomas and solid tumors have acceptable outcome with current risk adapted multimodality treatment. Especially, in lymphomas overall survival rates have reached the 90% level or higher. Because of the rarity of randomized prospective trials on hematopoietic stem cell transplantation in children with solid tumors the EBMT registry remains an important source of information. Decisions for hematopoietic stem cell transplantation should ideally be based on prospective trials like in high-risk neuroblastoma. In this study, indications and results of the hematopoietic stem cell transplantation in children with solid tumors was reviewed shortly in light of current literature.

Anahtar Kelimeler

Hematopoietic stem cell transplantation, lymphomas, solid tumors, children

Solid Tümörlerde Hematopoetik Kök Hücre Nakli

Öz

Güncel, riske dayalı multimodal tedavi şemalarıyla çocukluk çağı lenfomaları ve solid tümörlerinde kabul edilebilir sonuçlar alınmaktadır. Özellikle lenfomalarda genel sağkalım % 90 ve üzerine çıkmıştır. Çocukluk çağında solid tümörlü hastalarda hematopoetik kök hücre nakli ile ilgili prospektif randomize çalışmaların bulunmayışı nedeniyle EBMT kayıtları önemli bir kaynak oluşturmaktadır. İdeal olarak, kök hücre nakli ile ilgili kararların yüksek riskli nöroblastomda olduğu gibi prospektif çalışmalara dayandırılması gerekmektedir. Bu çalışmada, güncel literatür bilgileri esas alınarak çocukluk çağında solid tümörlü hastalarda kök hücre nakli ile ilgili endikasyon ve sonuçlar kısaca gözden geçirilmiştir.

Anahtar Kelimeler

Hematopoetik kök hücre nakli, lenfomalar, solid tümörler, çocuklar

Kaynakça

• Ladenstein R, Pötscheger U. High-dose chemotherapy and HSCT in children and adolescents with solid tumors in Europe In Thomas' Hematopoietic Cell Transplantation, 4th Edition (Eds FR Appelbaum, SJ Forman, RS Negrin, KG Blume):599-611. West Sussex, UK, Wiley-Blackwell, 2009. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transplantation for hematological diseases, solid tumors and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010; 45:219-34.
• Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003; 31:667-78.
• Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010; 16:223-30.
• Claviez A. HSCT for lymphomas in children and adolescents. In In Thomas' Hematopoietic Cell Transplantation, 4th Edition (Eds FR Appelbaum, SJ Forman, RS Negrin, KG Blume):531-42. West Sussex, UK, Wiley-Blackwell, 2009.